期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

STI571耐药机制及其对策的研究进展

Resistance Mechanism of ST1571 and Its Prevention Research——Review
下载PDF
导出
摘要 STI5 71是BCR ABL酪氨酸激酶靶向抑制剂 ,是一种新型的抗肿瘤制剂 ,已成功应用于白血病的治疗。尽管该药可以有效的抑制BCR ABL酪氨酸激酶活性 ,但仍有相当一部分白血病患者对其产生耐药性。本文就近年来STI5 STI571 is a new antileukemia agent targeting BCR-ABL tyrosine kinase and succes sfully used in trentment of leukemia patients. Despite strong efficacy of the tyrosine kinase inhibitor STI571,resistance has been observed in a significant proportion of leukemia patients.This review focuses on the diverse mechanisms of ST1571 resistance and its preventive measu res.
作者 周霞 侯健
机构地区 第二军医大学长征医院血液科
出处 《中国实验血液学杂志》 CAS CSCD 2004年第5期713-717,共5页 Journal of Experimental Hematology
关键词 STI571 耐药 慢性髓系白血病 STI571 drug resistance CML
分类号 R979.1 [医药卫生—药品] R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Gambacorti-Passerini C, Barni R, Ie Coutre P, et al. Role of alpha1acid glycoprotein in the in vivo resistance of human BCR-ABL ( + )leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst,2000; 92:1641 - 1650
  • 2Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib(STI571
  • 3Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002; 2: 117 - 125
  • 4Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al.Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 2002; 100: 1014- 1018
  • 5Hofmann WK, de-Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet, 2002; 359(9305 :4
  • 6Gambacorti-Passerini C, Barni R, Le-Coutre P, et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL ( + )leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst,2000; 92: 1641- 1650
  • 7Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.Blood, 1995; 86:726-736
  • 8Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamyc
  • 9La-Rosee P, Corbin AS, Stoffregen EP, et al. Activity of the BcrAbl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec,STI571). Cancer Res, 2002; 62: 7149- 7153
  • 10Yu C, Krystal G, Varticovski L, et al. Pharmacologeic mitogenactivated protein/ extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human l
中国实验血液学杂志
2004年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部